Danmei Zhang, Klara Dorman, C Benedikt Westphalen, Michael Haas, Steffen Ormanns, Jens Neumann, Max Seidensticker, Jens Ricke, Enrico N De Toni, Frederick Klauschen, Hana Algül, Timo Reisländer, Stefan Boeck, Volker Heinemann
For decades, treatment of advanced biliary tract cancer (BTC) was confined to the use of chemotherapy. In recent years however, the number of therapeutic options available for patients with unresectable BTC have drastically increased, with immunotherapy and targeted treatment gradually joining the ranks of guideline-recommended treatment regimens. The aim of the present review is to summarise the current knowledge on unresectable BTC focusing on epidemiology, anatomical distribution and current strategies for systemic treatment...
April 12, 2024: European Journal of Cancer
Elena Guerini-Rocco, Federica Bellerba, Alberto Concardi, Sergio Vincenzo Taormina, Giulio Cammarata, Caterina Fumagalli, Aliana Guerrieri-Gonzaga, Debora Macis, Eliza Del Fiol Manna, Emanuela Balladore, Maria Cannone, Paolo Veronesi, Nicola Fusco, Bernardo Bonanni, Giuseppe Viale, Massimo Barberis, Sara Gandini, Matteo Lazzeroni
BACKGROUND AND AIM: Ductal carcinoma in situ (DCIS) is a non-obligate precursor of invasive breast cancer with highly variable clinical behavior, but risk stratification is still challenging. We sought to identify immune-related gene expression signatures of pure DCIS associated with different risks of breast cancer recurrence. METHODS: A retrospective nested case-control study of 143 pure DCIS was performed including 70 women with subsequent ipsilateral breast event (IBE, in situ or invasive; cases) and 73 DCIS women with no IBE and matched for age, tumor size, treatment, hormone receptors/HER2 status, and follow-up time (controls)...
April 12, 2024: European Journal of Cancer
Jorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, Eric Raymond, Philippe Ruszniewski, Matthew H Kulke, Enrique Grande, Rocío García Carbonero, Daniel Castellano, Ramón Salazar, Toni Ibrahim, Alex Teule, Vicente Alonso, Nicola Fazio, Juan W Valle, Salvatore Tafuto, Ana Carmona, Victor Navarro, Jaume Capdevila
No abstract text is available yet for this article.
April 11, 2024: European Journal of Cancer
Samer Al Hadidi
No abstract text is available yet for this article.
April 9, 2024: European Journal of Cancer
Wouter H Zwart, Sofieke J D Temmink, Geke A P Hospers, Corrie A M Marijnen, Hein Putter, Iris D Nagtegaal, Lennart Blomqvist, Elma Meershoek-Klein Kranenbarg, Annet G H Roodvoets, Anna Martling, Cornelis J H van de Velde, Bengt Glimelius, Koen C M J Peeters, Boudewijn van Etten, Per J Nilsson
BACKGROUND: A pathological complete response (pCR) following chemoradiation (CRT) or short-course radiotherapy (scRT) leads to a favourable prognosis in patients with rectal cancer. Total neo-adjuvant therapy (TNT) doubles the pCR rate, but it is unknown whether oncological outcomes remain favourable and whether the same characteristics are associated with pCR as after CRT. METHODS: Comparison between patients with pCR in the RAPIDO trial in the experimental [EXP] (scRT, chemotherapy, surgery, as TNT) and standard-of-care treatment [STD] (CRT, surgery, postoperative chemotherapy depending on hospital policy) groups...
April 7, 2024: European Journal of Cancer
Alessandra Raimondi, Young Woo Kim, Won Ki Kang, Ruth E Langley, Yoon Young Choi, Kyoung-Mee Kim, Matthew Guy Nankivell, Giovanni Randon, Myeong-Cherl Kook, Ji Yeong An, Heike I Grabsch, Michele Prisciandaro, Federico Nichetti, Sung Hoon Noh, Tae Sung Sohn, Sung Kim, Andrew Wotherspoon, Federica Morano, David Cunningham, Jeeyun Lee, Jae-Ho Cheong, Elizabeth Catherine Smyth, Filippo Pietrantonio
BACKGROUND: Surgery plus peri-operative/adjuvant chemotherapy is the standard of care for locally advanced GC/GEJC, though with unsatisfactory results. dMMR/MSI-high tumors have better prognosis and scant benefit from chemotherapy as compared to pMMR/MSS ones. The differential outcome of therapies in terms of safety and efficacy according to sex is still debated in GC/GEJC patients. METHODS: We previously performed an individual patient data pooled analysis of MAGIC, CLASSIC, ITACA-S, and ARTIST trials including GC/GEJC patients treated with surgery alone or surgery plus peri-operative/adjuvant chemotherapy to assess the value of MSI status...
April 4, 2024: European Journal of Cancer
Nicholas Gravbrot, Christopher R Weil, Cristina M DeCesaris, David K Gaffney, Gita Suneja, Lindsay M Burt
No abstract text is available yet for this article.
April 2, 2024: European Journal of Cancer
Valentina Tuninetti, Elisa Virano, Vanda Salutari, Andrea Ricotti, Carmela Pisano, Monika Ducceschi, Giacinto Turitto, Giuseppa Scandurra, Maria Cristina Petrella, Valeria Forestieri, Monica Rizzetto, Serafina Mammoliti, Grazia Artioli, Raffaella Cioffi, Lucia Borsotti, Marco Bellero, Chiara Rognone, Vittoria Carbone, Gabriella Ferrandina, Mara Mantiero, Carmen Azzolina, Eleonora Geninatti, Sandro Pignata, Giorgio Valabrega
BACKGROUND: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients with advanced CC treated with cemiplimab in Italy. METHODS: The primary objective of the study was to assess the feasibility and the replicability of the initial results in a real world setting of cemiplimab nominal use...
March 30, 2024: European Journal of Cancer
Sujith Baliga, Ahmad K Abou-Foul, Pablo Parente, Petr Szturz, Juliette Thariat, Aditya Shreenivas, Paul Nankivell, Federica Bertolini, Julian Biau, Dukagjin Blakaj, Sinead Brennan, Aina Brunet, Thiago Bueno De Oliveira, Barbara Burtness, Alberto Carral Maseda, Velda Ling-Yu Chow, Melvin Lk Chua, Mischa de Ridder, Satya Garikipati, Nobuhiro Hanai, Francis Cho Hao Ho, Shao Hui Huang, Naomi Kiyota, Konrad Klinghammer, Luiz P Kowalski, Dora L Kwong, Lachlan J McDowell, Marco Carlo Merlano, Sudhir Nair, Panagiota Economopoulou, Jens Overgaard, Amanda Psyrri, Silke Tribius, John Waldron, Sue S Yom, Hisham Mehanna
The Head and Neck Cancer International Group (HNCIG) has undertaken an international modified Delphi process to reach consensus on the essential data variables to be included in a minimum database for HNC research. Endorsed by 19 research organisations representing 34 countries, these recommendations provide the framework to facilitate and harmonise data collection and sharing for HNC research. These variables have also been incorporated into a ready to use downloadable HNCIG minimum database, available from the HNCIG website...
March 30, 2024: European Journal of Cancer
Emanuel Bührer, David D'Haese, Gedske Daugaard, Ronald de Wit, Costantine Albany, Alexey Tryakin, Karim Fizazi, Olof Stahl, Jourik A Gietema, Ugo De Giorgi, Fay H Cafferty, Aaron R Hansen, Torgrim Tandstad, Robert A Huddart, Andrea Necchi, Christopher J Sweeney, Xavier Garcia-Del-Muro, Daniel Y C Heng, Anja Lorch, Michal Chovanec, Eric Winquist, Peter Grimison, Darren R Feldman, Angelika Terbuch, Marcus Hentrich, Carsten Bokemeyer, Helene Negaard, Christian Fankhauser, Jonathan Shamash, David J Vaughn, Cora N Sternberg, Axel Heidenreich, Laurence Collette, Silke Gillessen, Jörg Beyer
AIMS: To resolve the ongoing controversy surrounding the impact of teratoma (TER) in the primary among patients with metastatic testicular non-seminomatous germ-cell tumours (NSGCT). PATIENTS AND METHODS: Using the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium database, we compared the survival probabilities of patients with metastatic testicular GCT with TER (TER) or without TER (NTER) in their primaries corrected for known prognostic factors...
March 30, 2024: European Journal of Cancer
James A Thomas, Bradley J Kendall, Graeme A Macdonald, Aaron P Thrift
No abstract text is available yet for this article.
March 29, 2024: European Journal of Cancer
Pien Debets, Koen M A Dreijerink, Anton Engelsman, Max Dahele, Harm R Haak, Rebecca V Steenaard, Ellen Kapiteijn, Eleonora Corssmit, Willemien Menke-van der Houven van Oordt
No abstract text is available yet for this article.
March 27, 2024: European Journal of Cancer
Nicolas Roussot, Guillaume Constantin, Isabelle Desmoulins, Anthony Bergeron, Laurent Arnould, Françoise Beltjens, Didier Mayeur, Courèche Kaderbhai, Audrey Hennequin, Clémentine Jankowski, Marie Martine Padeano, Hélène Costaz, Sarah Jacinto, Eloise Michel, Alix Amet, Charles Coutant, Brigitte Costa, Christelle Jouannaud, Mathilde Deblock, Christelle Levy, Jean-Marc Ferrero, Pierre Kerbrat, Etienne Brain, Marie-Ange Mouret-Reynier, Bruno Coudert, Aurélie Bertaut, Sylvain Ladoire
BACKGROUND: The CPS+EG scoring system was initially described in unselected early breast cancer (eBC) patients treated with neoadjuvant chemotherapy (NAC), leading to refined prognostic stratification, and thus helping to select patients for additional post-NAC treatments. It remains unknown whether the performance is the same in new biological breast cancer entities such as the HER2-low subtype. PATIENTS AND METHODS: Outcomes (disease-free (DFS) and overall survival OS)) of 608 patients with HER2-non amplified eBC and treated with NAC were retrospectively analyzed according to CPS-EG score...
March 26, 2024: European Journal of Cancer
Alberto Picca, Mehdi Touat, Lisa Belin, Carole Gourmelon, Vincent Harlay, Stefania Cuzzubbo, Elizabeth Cohen-Jonathan Moyal, Charlotte Bronnimann, Anna Luisa Di Stefano, Isaura Laurent, Julie Lerond, Catherine Carpentier, Franck Bielle, François Ducray, Caroline Dehais
BACKGROUND: Novel effective treatments are needed for recurrent IDH mutant high-grade gliomas (IDHm HGGs). The aim of the multicentric, single-arm, phase II REVOLUMAB trial (NCT03925246) was to assess the efficacy and safety of the anti-PD1 Nivolumab in patients with recurrent IDHm HGGs. PATIENTS AND METHODS: Adult patients with IDHm WHO grade 3-4 gliomas recurring after radiotherapy and ≥ 1 line of alkylating chemotherapy were treated with intravenous Nivolumab until end of treatment (12 months), progression, unacceptable toxicity, or death...
March 22, 2024: European Journal of Cancer
Alizé A Rogge, Gregor Liegl, Claire Snyder, Matthias Rose, Sandra Nolte
OBJECTIVE: The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 is a frequently used cancer-specific health-related quality of life (HRQoL) questionnaire. To aid interpretation of data obtained via EORTC QLQ-C30, general population norm data have been published for many countries. However, despite its frequent use in the United States, no normative data by sex and age exist to date. Therefore, this study aimed to generate sex- and age-specific EORTC QLQ-C30 normative data for the United States...
March 21, 2024: European Journal of Cancer
Mathilde Moreau, Emily Alouani, Clémence Flecchia, Antoine Falcoz, Claire Gallois, Edouard Auclin, Thierry André, Romain Cohen, Antoine Hollebecque, Anthony Turpin, Simon Pernot, Thérèse Masson, Frederic Di Fiore, Marie Dutherge, Thibault Mazard, Vincent Hautefeuille, Jean-Luc Van Laethem, Christelle De la Fouchardière, Géraldine Perkins, Meher Ben-Abdelghani, Francesco Sclafani, Thomas Aparicio, Stefano Kim, Dewi Vernerey, Julien Taieb, Rosine Guimbaud, David Tougeron
BACKGROUND: One randomized phase III trial comparing chemotherapy (CT) with immune checkpoint inhibitors (ICI) has demonstrated significant efficacy of ICI in deficient DNA mismatch repair system/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer. However, few studies have compared ICI with CT in other advanced dMMR/MSI-H digestive tumors. METHODS: In this multicenter study, we included patients with advanced dMMR/MSI-H non-colorectal digestive tumors treated with chemotherapy and/or ICIs...
March 21, 2024: European Journal of Cancer
Vadim Lesan, Timothée Olivier, Vinay Prasad
Kaplan-Meier analysis hinges on the assumption that patients who are censored- lost to follow-up, or only recently enrolled on the study- are no different, on average, than patients who are followed. As such, censoring these patients- omitting their future information and taking the average of those who were followed- should not dramatically change the overall estimate. Yet, in a recent clinical trial, two sets of censoring rules- one favored by trialists and one favored by the US Food and Drug Administration- were applied to a progression-free survival (PFS) estimate...
March 20, 2024: European Journal of Cancer
E G M van Geffen, J M A Langhout, S J A Hazen, T C Sluckin, S van Dieren, G L Beets, R G H Beets-Tan, W A A Borstlap, J W A Burger, K Horsthuis, M P W Intven, A G J Aalbers, K Havenga, A W K S Marinelli, J Melenhorst, J Nederend, H M U Peulen, H J T Rutten, W H Schreurs, J B Tuynman, C Verhoef, J H W de Wilt, C A M Marijnen, P J Tanis, M Kusters, On Behalf Of The Dutch Snapshot Research Group
BACKGROUND: In the Netherlands, use of neoadjuvant radiotherapy for rectal cancer declined after guideline revision in 2014. This decline is thought to affect the clinical nature and treatability of locally recurrent rectal cancer (LRRC). Therefore, this study compared two national cross-sectional cohorts before and after the guideline revision with the aim to determine the changes in treatment and survival of LRRC patients over time. METHODS: Patients who underwent resection of primary rectal cancer in 2011 (n = 2094) and 2016 (n = 2855) from two nationwide cohorts with a 4-year follow up were included...
March 20, 2024: European Journal of Cancer
Julia K Winkler, Katharina S Kommoss, Ferdinand Toberer, Alexander Enk, Lara V Maul, Alexander A Navarini, Jeremy Hudson, Gabriel Salerni, Albert Rosenberger, Holger A Haenssle
IMPORTANCE: Total body photography for skin cancer screening is a well-established tool allowing documentation and follow-up of the entire skin surface. Artificial intelligence-based systems are increasingly applied for automated lesion detection and diagnosis. DESIGN AND PATIENTS: In this prospective observational international multicentre study experienced dermatologists performed skin cancer screenings and identified clinically relevant melanocytic lesions (CRML, requiring biopsy or observation)...
March 19, 2024: European Journal of Cancer
Rikke B Holmstroem, Sidsel Pedersen, Rebecca Jurlander, Kasper Madsen, Marco Donia, Christina H Ruhlmann, Henrik Schmidt, Charlotte A Haslund, Lars Bastholt, Inge Marie Svane, Eva Ellebaek
BACKGROUND: Clinical trials have demonstrated promising outcomes for adjuvant immunotherapy in patients with resected melanoma. Real-life data provide valuable insights to support patient guidance and treatment decisions. METHODS: Observational population-based study examining a national cohort of patients with resected stage III-IV melanoma referred for adjuvant therapy. Data were extracted from the Danish Metastatic Melanoma Database (DAMMED). RESULTS: Between November 2018 and January 2022, 785 patients received adjuvant anti-PD-1...
March 19, 2024: European Journal of Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.